Skip to main content
Blood Advances logoLink to Blood Advances
. 2020 Sep 28;4(19):4606. doi: 10.1182/bloodadvances.2020003378

Thapa B, Caimi PF, Ardeshna KM, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020;4(16):3850-3852.

PMCID: PMC7556140  PMID: 32986790

In the author affiliations on page 3850, Carmelo Carlo-Stella’s affiliation should read, “Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Humanitas University, Rozzano, Milan, Italy.” In addition, on page 3852, this author’s ORCID profile was omitted. The errors have been corrected in the published article.


Articles from Blood Advances are provided here courtesy of The American Society of Hematology

RESOURCES